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Osteoclasts are derived from myeloid lineage cells, and their differentiation is supported 
by various osteotropic factors, including the tumor necrosis factor (TNF) family member 
TNF-related activation-induced cytokine (TRANCE). Genetic deletion of TRANCE or its 
receptor, receptor activator of nuclear factor 
 
 
 
B (RANK), results in severely osteopetrotic 
mice with no osteoclasts in their bones. TNF receptor-associated factor (TRAF) 6 is a key 
signaling adaptor for RANK, and its deficiency leads to similar osteopetrosis. Hence, the 
current paradigm holds that TRANCE–RANK interaction and subsequent signaling via TRAF6 
are essential for the generation of functional osteoclasts. Surprisingly, we show that 
hematopoietic precursors from TRANCE-, RANK-, or TRAF6-null mice can become 
osteoclasts in vitro when they are stimulated with TNF-
 
 
 
 in the presence of cofactors such 
as TGF-
 
 
 
. We provide direct evidence against the current paradigm that the TRANCE–
RANK–TRAF6 pathway is essential for osteoclast differentiation and suggest the potential 
existence of alternative routes for osteoclast differentiation.
 
Osteoclasts are multinucleated cells responsible
for bone resorption and are derived from he-
matopoietic precursor cells (HPCs) of myeloid
lineage. It is currently thought that two critical
factors supplied by osteoblasts, macrophage CSF
(M-CSF) and TNF-related activation-induced
cytokine (TRANCE, also called receptor acti-
vator of NF-
 
 
 
B [RANK] ligand, osteoclast dif-
ferentiation factor, and osteoprotegerin ligand),
are essential for the differentiation and matura-
tion of osteoclast precursors in bones (1, 2).
M-CSF–defective mice (op/op) show an osteo-
petrotic phenotype that can spontaneously
reverse with age or be rescued by transgenic
expression of Bcl-2. Mice deficient in either
TRANCE or its receptor RANK also show an
osteopetrotic phenotype that is caused by the
complete lack of osteoclasts in their bones.
TRANCE KO mice, however, cannot be
rescued by transgenic expression of Bcl-2 (3),
supporting the idea that TRANCE is a differ-
entiation factor for osteoclasts. Ex vivo recom-
binant TRANCE, in combination with M-CSF,
can induce osteoclast formation from mouse
bone marrow cells, spleen cells, or human
peripheral blood cells without stromal cells or
osteoblasts. Moreover, recombinant TRANCE
alone induces the differentiation of the mono-
cytic cell line RAW264.7 into osteoclasts (1, 2).
Most TNF receptor family members, in-
cluding RANK, interact with a family of
adaptor proteins called TNF receptor-associ-
ated factors (TRAFs) (4). Among the known
TRAF family members, TRAF2, TRAF5,
and TRAF6 can activate transcription factors,
such as NF-
 
 
 
B and AP-1, that are required for
osteoclast differentiation (4). RANK interacts
with most of the TRAF family members
(4); however, TRAF6 seems to play a critical
role in osteoclast differentiation mediated by
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RANK. Three independent TRAF6 KO mouse lines have
been reported, and all exhibit osteopetrosis (5–7). Collec-
tively, it has been proposed that TRANCE–RANK interac-
tion and subsequent signaling via TRAF6 are essential for
the differentiation of mature osteoclasts (1, 2, 4).
We show that osteoclasts can be generated from HPCs of
TRANCE, RANK, or TRAF6 KO mice. These results
provide direct evidence that osteoclast differentiation in vitro
can occur independently of the TRANCE–RANK interac-
tion and its signaling via TRAF6. Therefore, our data chal-
lenge the current paradigm for osteoclast differentiation and
suggest the possibility that alternative pathways may exist
for osteoclast differentiation that is independent of the
TRANCE axis.
 
RESULTS AND DISCUSSION
Is the TRANCE–RANK interaction essential for 
osteoclast differentiation?
 
We revisited the issue of whether the TRANCE–RANK in-
teraction is essential for osteoclast differentiation. Although
this may be counterintuitive because it has been firmly estab-
lished that TRANCE or RANK KO mice do not have any
osteoclast in their bones, the following observations serve as
the basis of this study. First, it was reported that TNF-
 
 
 
 could
support osteoclastogenesis in the presence of osteoprotegerin,
an inhibitor of TRANCE–RANK interactions (8–10). These
results suggest that TNF-
 
 
 
 might induce osteoclast differenti-
ation in the absence of TRANCE–RANK interactions.
However, the issue of whether TNF-
 
 
 
 is a direct inducer of
Figure 1. TNF- –induced osteoclastogenesis in WT or TRANCE-
deficient cells. (A–C) Osteoclast formation from WT or TRANCE-deficient 
osteoclast precursors. (A and B) BMMs were derived from bone marrow 
cells of WT mice by culturing them for 3 d with M-CSF alone or with
M-CSF   TGF-  as indicated. BMMs were further cultured with M-CSF 
alone or with M-CSF   TNF-  as indicated. (C) Splenocytes isolated from 
TRANCE KO mice were cultured for 3 d with M-CSF alone or with M-CSF  
TGF-  in the presence of 5  g/ml RANK-Fc to generate BMMs, which 
were subsequently treated with M-CSF alone, M-CSF/TNF- , or M-CSF/
TNF- /RANK-Fc (5  g/ml), as indicated. Cultured cells were fixed and 
stained for TRAP. (D and E) TRANCE-deficient osteoclast precursors were 
prepared by culturing HPCs with M-CSF and TGF- . F-actin ring staining 
(D) and a pit formation assay (E) on TRANCE-deficient cells that were 
subsequently cultured for 3 d with the indicated conditions are shown. 
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Figure 2. TNF- –induced osteoclastogenesis from WT or RANK-
deficient cells. (A) Osteoclast formation from WT or RANK-deficient 
osteoclast precursors. Spleen cells were incubated for 3 d with M-CSF 
alone or with M-CSF   TGF-  to generate osteoclast precursors as 
indicated. Precursors were further cultured with M-CSF alone, M-CSF/
TRANCE, or M-CSF/TNF- . Cultured cells were fixed and stained for TRAP. 
(B) Osteoclast precursors prepared with M-CSF and TGF-  were further 
cultured for 3 d with M-CSF/TNF-  and fixed and stained for F-actin rings 
and TRAP. (C) Osteoclast precursors were prepared by culturing HPCs with 
M-CSF and TGF-  for 3 d. BMMs were incubated for an additional 3 d with 
M-CSF alone or with M-CSF/TRANCE for WT cells. RANK-deficient osteo-
clast precursors prepared with M-CSF   TGF-  were cultured for 3 d with 
M-CSF/TNF-  and an additional day with M-CSF/TNF-  in the presence or 
absence of IL-1 as indicated. Cells were subjected to real-time PCR analysis 
for TRAP, cathepsin K, MMP-9, calcitonin receptor, carbonic anhydrase II, 
and NFATc1. Values were normalized to 18S RNA expression. (D) Osteo-
clast precursors were prepared and cultured as described in C with the 
indicated stimuli, and dentine slices were stained with toluidine blue. 
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osteoclast differentiation is still controversial. Lam et al.
showed that TNF-
 
 
 
 alone failed to induce osteoclast differen-
tiation from murine precursors in similar culture conditions
(11). Second, although no osteoclasts can be identified in the
bones of TRANCE or RANK KO mice, this may not be
simply because of the complete failure of osteoclastogenesis.
For example, impaired osteoclast differentiation superimposed
on a shortened lifespan may also explain the observed pheno-
type in TRANCE or RANK KO mice. Indeed, TRANCE
is a survival factor for differentiated osteoclasts (12).
To test the hypothesis that the TRANCE–RANK inter-
action may not be essential for osteoclast differentiation, we
examined whether TNF-
 
 
 
 can substitute for TRANCE in
inducing osteoclasts from HPCs. Osteoclast precursors were
prepared with M-CSF from bone marrow cells and were
further cultured with M-CSF and TNF-
 
 
 
. Similar to Lam et
al., we could not find obvious multinucleated tartrate-resis-
tant acid phosphatase (TRAP)–positive osteoclasts (TRAP
 
 
 
mononuclear cells [MNCs]) after treatment with TNF-
 
 
 
, al-
though TRAP
 
 
 
 MNCs were observed (Fig. 1, A and B). To
test the possibility that our culture conditions might have in-
sufficient cofactors, we examined the role of TGF-
 
 
 
 in this
process. We chose TGF-
 
 
 
 for this study because it was
shown to synergize with TRANCE in the induction of os-
teoclast differentiation and to be prevalent in the bone (13,
14) (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20050978/DC1). When TGF-
 
 
 
 was added with
M-CSF to prepare osteoclast precursors from bone marrow
cells, subsequent TNF-
 
 
 
 treatment resulted in a large num-
ber of TRAP
 
 
 
 MNCs (Fig. 1, A and B), and these formed
actin rings (not depicted). Such results suggest that if proper
cofactors are included to prepare osteoclast precursors, TNF-
 
 
 
can induce the formation of osteoclasts.
To rule out an indirect effect of TNF-
 
 
 
 on osteoclast
formation through up-regulation of TRANCE, we pre-
pared osteoclast precursors by culturing splenocytes from
TRANCE KO mice with M-CSF alone or with M-CSF 
 
 
 
TGF-
 
 
 
 for 3 d. To minimize the potential effect of
TRANCE in the serum, we added RANK-Fc to the culture
at a concentration 5 
 
 
 
g/ml, which completely inhibits os-
teoclast formation induced by recombinant soluble
TRANCE (Fig. 1 C). Even in the presence of an excessive
amount of RANK-Fc, TRAP
 
 
 
 MNCs were readily formed
by M-CSF and TNF-
 
 
 
 treatment when osteoclast precursors
from TRANCE KO mice were prepared with M-CSF 
 
 
 
TGF-
 
 
 
 (Fig. 1 C). TRANCE-deficient TRAP
 
 
 
 MNCs in-
duced by TNF-
 
 
 
 successfully formed actin rings (Fig. 1 D);
however, TNF-
 
 
 
–induced TRANCE-deficient osteoclasts
failed to resorb bone (Fig. 1 E). TRAF6 activation has been
reported to be important for osteoclast activation (15). Be-
cause TRAF6 is not activated by TNF-
 
 
 
, we next tested
whether TRANCE-deficient osteoclasts can be further ac-
tivated by IL-1, which activates TRAF6 (16). When
TRANCE-deficient osteoclast precursors, prepared by
M-CSF 
 
  
 
TGF-
 
 
 
, were cultured with TNF-
 
 
 
 and IL-1 in
the presence of M-CSF, pits were clearly formed on dentine
slices (Fig. 1 E).
Similar experiments were also performed with spleen
cells from RANK KO mice and showed that TNF-
 
 
 
 in-
duced TRAP
 
 
 
 MNCs when osteoclast precursors cells were
prepared in the presence of M-CSF 
 
  
 
TGF-
 
 
 
 (Fig. 2 A).
These cells formed actin rings and expressed most of the mo-
lecular markers that characterize mature osteoclasts (Fig. 2, B
and C, and Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20050978/DC1). However, these cells
failed to form resorption pits (Fig. 2 D). Surprisingly, as with
TRANCE-deficient cells, combined treatment with M-CSF,
TNF-
 
 
 
, and IL-1 induced bone-resorbing osteoclasts from
RANK-deficient osteoclast precursors that were prepared
with M-CSF and TGF-
 
 
 
 (Fig. 2 D).
Collectively, these data provide rather surprising but di-
rect evidence that osteoclast formation can be induced in vitro
by a mechanism that is independent of TRANCE–RANK, if
proper factors are included during osteoclast precursor prepa-
ration. In this study, these factors were M-CSF and TGF-
 
 
 
,
followed by treatment with M-CSF, TNF-
 
 
 
, and IL-1 to in-
duce differentiation and activation of osteoclasts.
How TNF-
 
 
 
 induces osteoclast differentiation indepen-
dent of TRANCE–RANK is unclear at this time. Although
TRAF2 and TRAF5 are critical signaling adapters for TNF
receptors, TRAF2- or TRAF5-deficient cells differentiate
into mature osteoclasts upon TNF-
 
 
 
 treatment if osteoclast
precursors are prepared with M-CSF and TGF-
 
 
 
 (unpub-
lished data). TRAF6 is also dispensable for TNF-
 
 
 
–induced
osteoclast differentiation (Fig. S3, A–C, available at http://
www.jem.org/cgi/content/full/jem.20050978/DC1). How-
ever, TRAF6 appears to be critical for the complete activa-
tion of osteoclasts because TRAF6-deficient osteoclasts de-
rived with TNF-
 
 
 
 failed to resorb bone even in the presence
of IL-1 (Fig. S3 D). It is of interest that, although TNF-
 
 
 
alone fails to activate nuclear family of activated T cells
(NFAT) c1, it can strongly induce the transcription of
Figure 3. Induction of NFATc1. Osteoclast precursors were derived 
from bone marrow cells of WT mice by culture with M-CSF alone or with 
M-CSF/TGF-  and subsequently stimulated with TRANCE or TNF-  for the 
indicated times. M-CSF was present at all times. Samples were subjected 
to real-time PCR using NFATc1-specific primers. NFATc1 mRNA induction 
was normalized to HPRT expression. 
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NFATc1 to a level similar to that induced by TRANCE if
osteoclast precursors are prepared with M-CSF and TGF-
 
 
 
(Fig. 3). It is unclear how TNF-induced early signaling
events vary in osteoclast precursors prepared with M-CSF
and TGF-
 
 
 
. Nevertheless, it appears that the ability of dis-
tinct stimuli to induce NFATc1 above a critical threshold is
an important step in this process. This is consistent with the
finding that overexpression of NFATc1 is sufficient to in-
duce osteoclast differentiation (17) and is consistent with
data demonstrating that high levels of CD40 stimulation can
induce osteoclast differentiation independent of TRANCE–
RANK activation (18).
 
Role of TRAF6 in osteoclast activation
 
TRAF6 KO mice were generated by three independent
schemes, and all showed severe osteopetrosis (5–7) (Fig.
S4, available at http://www.jem.org/cgi/content/full/
jem.20050978/DC1). However, there were some discrepan-
cies in the phenotypes of these mice. For example, though
functionally defective, normal numbers of TRAP
 
 
 
 MNCs
were observed in the long bone of TRAF6 KO mice re-
ported by Lomaga et al. (6). However, Naito et al. reported
no TRAP
 
 
 
 MNCs in their mice (5). In contrast, we found
that the number of TRAP
 
 
 
 MNCs is considerably reduced,
but still detectable, in the bones of TRAF6 KO mice (Fig.
S4). One possible explanation for these discrepancies is that
different regions of TRAF6 were deleted in the three lines
and, thus, there may be variations in the leakiness of null mu-
tations among the models. However, none of the TRAF6-
null mice showed detectable levels of mutant or WT TRAF6
protein. Moreover, HPCs from all of the different TRAF6
KO lines failed to become osteoclasts in vitro when stimu-
lated with M-CSF and TRANCE (19) (Boyle, W., personal
communication; Fig. 4, A and B, left column). These results
make it unlikely that there was residual TRAF6 protein func-
tion in any of the TRAF6 mutant lines. Thus, various exper-
iments, both in vivo and in vitro, with three different lines of
TRAF6 KO mice failed to resolve a critical question related
to the role of TRAF6 in TRANCE-induced osteoclast dif-
ferentiation
 
: 
 
is TRAF6 essential for osteoclast differentiation
induced by TRANCE–RANK interaction?
To investigate the importance of TRAF6 in TRANCE-
induced osteoclast differentiation in the presence of cofac-
tors, splenocytes from TRAF6 KO mice were collected and
cultured for 3 d in the presence of M-CSF and were
then used as osteoclast precursors. As expected, no TRAP
 
 
 
MNCs were detected by subsequent treatment with M-CSF
and TRANCE (Fig. 4, A and B), which is consistent with
previous experiments (19) (Boyle, W., personal communica-
tion). However, when TRAF6-deficient osteoclast precur-
sors were prepared by cotreatment with M-CSF and
TGF-
 
 
 
, TRAF6-deficient TRAP
 
 
 
 MNCs were generated
by subsequent treatment with M-CSF and TRANCE (Fig.
4, A and B). These cells expressed high levels of TRAP or
osteoclast-associated receptor (OSCAR), markers that are
specific for authentic osteoclasts (Fig. S5, available at http://
www.jem.org/cgi/content/full/jem.20050978/DC1). To
determine whether TRAF6-deficient TRAP
 
 
 
 MNCs were
Figure 4. TRANCE-induced osteoclastogenesis in WT or TRAF6-
deficient cells. (A and B) Osteoclast formation from WT or TRAF6-deficient 
cells.  Spleen cells were incubated for 3 d with M-CSF alone or with M-CSF   
TGF-  to generate osteoclast precursors, as indicated, and further 
cultured with M-CSF alone or M-CSF   TRANCE.  Cultured cells were fixed 
and stained for TRAP. F-actin ring staining (C) and a pit formation assay 
(D) on WT or TRAF6-deficient TRAP  MNCs derived from osteoclast 
precursors prepared with M-CSF and TGF-  are shown.THE ALTERNATIVE PATHWAY OF OSTEOCLASTOGENESIS | Kim et al. 594
functional, F-actin ring formation and bone resorption
on dentine slices were assessed. Unlike WT osteoclasts,
TRANCE-induced TRAF6-deficient TRAP  MNCs failed
to form actin rings or resorb bone (Fig. 4, C and D).
These results have several implications. First, TRAF6-
deficient HPCs can be induced to differentiate into osteo-
clasts by TRANCE if the proper cofactors, such as TGF- ,
are provided in the culture. This result implies that TRAF6
is not likely to be essential for osteoclast differentiation, in
contrast to what has been previously proposed (19) (Boyle,
W., personal communication). Thus, the varying degree of
osteoclast development observed in the three different lines
of TRAF6 KO mice may be caused by different cofactors
that vary with genetic background, age, or housing environ-
ment. Nevertheless, TRANCE-induced osteoclastogenesis is
still considerably reduced in the absence of TRAF6 (Fig. 4
A), implying that TRAF6 is a major signaling adaptor for
RANK during osteoclast differentiation. Second, TRAF6
seems to be critical for complete activation of osteoclasts,
even in the presence of excessive cofactors. Consistent with
our data, RANK–TRAF6 interactions have been implicated
for osteoclast cytoskeletal organization and resorptive func-
tion in vitro (15). Thus, in conjunction with our data that
IL-1/TRAF6 signals can induce osteoclast resorption (Fig. 1
and Fig. 2), the most critical role of TRAF6 is likely to be its
ability to activate mature osteoclasts to resorb bone.
Conclusion
Our study provides direct evidence that functional bone-
resorbing osteoclasts can be generated in vitro in the absence
of TRANCE–RANK if cultures are supplemented with the
proper factors. This is clearly against the current paradigm of
how an osteoclast is generated, which states that TRANCE–
RANK interactions are absolutely required. Our data do
not, however, refute the role of TRANCE–RANK as a ma-
jor regulator of osteoclast differentiation. Rather, our find-
ings suggest the possibility that an alternative pathway of os-
teoclast differentiation may exist in vivo.
Based on the limited published studies using TRANCE
or RANK KO mice, such alternative pathways have not
thus far been identified, even in a model of experimental ar-
thritis (20). Nonetheless, the attempt to elucidate alternative
pathways for osteoclast differentiation and the responsible
factors in vivo should be justifiable based on our study. Of
note, although we have used TNF-  and TGF-  to induce
osteoclasts in the absence of TRANCE–RANK in vitro, the
same factors may not be responsible for a putative alternative
pathway of osteoclast differentiation in vivo. The identifica-
tion of distinct osteoclast differentiation pathways will be
important to design better therapeutical approaches to treat
chronic inflammatory bone diseases.
MATERIALS AND METHODS
Reagents. All cell culture media and supplements were obtained from Life
Technologies. Soluble recombinant mouse TRANCE and RANK-Fc were
purified from insect cells as described previously (21), and recombinant hu-
man M-CSF was a gift from D. Fremont (Washington University, St.
Louis, MO). TNF- , IL-1, and TGF-  were purchased from R&D Sys-
tems. Texas red-X phalloidin was obtained from Molecular Probes.
Mice. C57BL/6 male mice (4–6 wk of age) were obtained from the Jack-
son Laboratory. The breeding and genotyping of mice deficient in
TRANCE, RANK, TRAF6, TRAF5, or TRAF2 was performed as previ-
ously described (7, 21–24).
Osteoclast formation. Murine osteoclasts were prepared from bone mar-
row cells or splenocytes. In brief, cells from bone marrow or spleens were
cultured in  -MEM containing 10% FBS with 5 ng/ml M-CSF for 16 h to
separate adherent cells from nonadherent cells. Nonadherent cells were har-
vested and cultured with 30 ng/ml M-CSF alone or with 30 ng/ml M-CSF
plus 1 ng/ml TGF- , as indicated in the figures. After 3 d of culture, float-
ing cells were removed, and the attached cells were used as bone marrow–
derived monocyte/macrophage precursors (BMMs). To generate osteo-
clasts, BMMs were further cultured with various combinations of 30 ng/ml
M-CSF, 100 ng/ml TRANCE, and 20 ng/ml TNF- , as indicated in the
figures. After an additional 3 d of culture, cells were fixed and stained for
TRAP. TRAP-positive multinucleated cells containing more than three
nuclei were considered multinucleated TRAP  osteoclasts. M-CSF was in-
cluded at all times. In some experiments, 5  g/ml RANK-Fc was added to
the cultures. All cells were cultured at 37 C and 5% CO2.
Pit formation assay and F-actin ring staining. Bone marrow cells or
splenocytes were incubated for 3 d with 30 ng/ml M-CSF alone or with 30
ng/ml M-CSF plus 1 ng/ml TGF-   to generate BMMs. BMMs were
placed on dentine slices and were cultured for an additional 3 d with various
combinations of 30 ng/ml M-CSF, 100 ng/ml TRANCE, 20 ng/ml
TNF- , and 10 ng/ml IL-1, as indicated in the figures. In Fig. 2, however,
10 ng/ml IL-1 was added only for one additional day after RANK-deficient
cells were cultured for 3 d with M-CSF and TNF- . The slices were then
recovered, cleaned by ultrasonication in 0.5 M NH4OH to remove adher-
ent cells, and stained with toluidine blue to visualize resorption pits. For
F-actin ring staining, BMMs prepared with M-CSF and TGF-  were fur-
ther cultured for 3 d with various combinations of 30 ng/ml M-CSF, 100
ng/ml TRANCE, 20 ng/ml TNF- , 10 ng/ml IL-1, and 5  g/ml RANK-Fc,
as indicated in the figures. Cultured cells were fixed and stained with Texas
red-X phalloidin.
RT-PCR. RT-PCR analysis was performed using cDNA from WT or
TRAF6-deficient osteoclasts. Spleen cells were incubated for 3 d with 30
ng/ml M-CSF alone or 30 ng/ml M-CSF plus 1 ng/ml TGF-  to generate
BMMs. BMMs were cultured for an additional 3 d with 30 ng/ml M-CSF
alone or with 30 ng/ml M-CSF plus 100 ng/ml TRANCE. Total RNA
was extracted from cultured cells using TRIZOL (Life Technologies). First-
strand cDNA was transcribed from 1  g of RNA using Superscript RT
(Life Technologies) according to the protocol provided by the supplier. The
PCR was performed at 94 C for 1 min, 55 C for 1 min, and 72 C for 1 min
for a total of 25 (for TRAP and hypoxanthine ribosyltransferase [HPRT])
or 30 (for OSCAR) cycles. The following primers were used: 5 -OSCAR,
5 -CTGCTGGTAACGGATCAGCTCCCCAGA-3 ; 3 -OSCAR, 5 -
CCAAGGAGCCAGAACCTTCGAAACT-3 ; 5 -TRAP, 5 -CAGTTG-
GCAGCAGCCAAGGAGGAC-3 ; 3 -TRAP, 5 -GTCCCTCAGGAGT-
CTAGGTATCAC-3 ; 5 -HPRT, 5 -GTAATGATCAGTCAACGGGG-
GAC-3 ; 3 -HPRT, 5 -CCAGCAAGCTTGCAACCTTAACCA-3 .
Real-time PCR. Quantitative real-time PCR was performed using the
TaqMan universal PCR master mix. TaqMan primers and probes were pur-
chased from Applied Biosystems. To make first-strand cDNA, 4  g RNA
was reverse transcribed in a 20- l reaction. The cDNA was diluted to five-
fold, and 4  l was used as a template in each PCR with PCR TaqMan uni-
versal master mix containing 1   PCR buffer and the appropriate concentra-JEM VOL. 202, September 5, 2005 595
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tions of gene-specific primers, the TaqMan probe, 5 mM MgCl2, 0.025 U
AmpliTaq Gold, and 0.2 mM dNTPs combined in a total volume of 25  l. A
negative cDNA control lacking reverse trancriptase was also included in each
assay. The PCR was performed at 95 C for 10 min (denaturation), 95 C for
15 s, and 60 C for 1 min for a total of 40 cycles. The cycle threshold (Ct) val-
ues, corresponding to the PCR cycle number at which fluorescence emission
in real time reaches a threshold above the baseline emission, were deter-
mined. The Ct value assigned to a particular well thus reflects the point dur-
ing the reaction at which a sufficient number of amplicons have accumulated
in that well to be at a point well above the baseline.
Histology. Osteoclasts were visualized by histochemical staining for
TRAP. In brief, tibiae were dissected, fixed in gluatraldehyde, demineral-
ized with EDTA, and embedded in glycol methacrylate. 3- m sections
were cut and mounted on glass slides without heating. Osteoclasts were
stained by incubation in chromogenic acid phosphatase substrate in the
presence of tartaric acid.
Online supplemental material. Fig. S1 shows the effect of TGF-  on
osteoclast differentiation. Fig. S2 depicts a real-time PCR analysis of
mRNA from WT or RANK-deficient osteoclasts. Fig. S3 shows TNF- –
induced osteoclastogenesis of WT and TRAF6-deficient cells. Fig. S4 de-
picts an osteopetrotic phenotype of TRAF6 KO mice. Fig. S5 shows an
RT-PCR analysis of mRNA from WT or TRAF6-deficient osteoclasts.
Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20050978/DC1.
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